BENGALURU: South Korean, Indian and Thai shares led declines in Asia on Wednesday, as a halt in more COVID-19 vaccine trials and concerns over China's property sector added to potential headwinds for the region's emerging markets.
Eli Lilly and Co joined Johnson & Johnson in pausing the clinical trial of its COVID-19 antibody treatment due to a safety concern, dragging Asian equities lower in line with their U.S. counterparts and prompting a shift to safer assets.
Already a subscriber? Log in.
Subscribe to win RM50 Touch 'n Go e-Voucher! More Info
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!